Multiple Sclerosis eEDSS – Data Science Point of View
Costas Boussios, Chief Data Scientist, OM1 details estimated EDSS score for Multiple Sclerosis were developed.
Showing 46-50 of 93 predictive & prescriptive analytics:
OM1 Unveils Patented, AI-powered Platform to Accelerate Personalized Medicine
April 13, 2023 BusinessWire Read the full release >> The digital phenotyping platform, PhenOM, is delivering personalized and actionable healthcare insights around diagnosis, treatment, risk, utilization, and clinical trials BOSTON–(BUSINESS WIRE)–OM1, a leading real-world data, outcomes and technology company with a focus on chronic conditions, today launched PhenOM™, its artificial intelligence-powered platform for personalized medicine. Calibrated[…]
Interview with OM1’s Jessica Paulus at SCOPE
Published on: March 9, 2023 Applied Clinical Trials Watch the Full Interview >> Key Learning Objectives: Challenges people encounter when working with RWD How can RWD help address gaps in care? How OM1 engages or supports health equity research using RWD
AI Uncovers Other Patients Like You to Support Doctors with ChatGPT
Watch the full interview from Healthcare IT about ChatGPT for un-diagnosed patients with Joseph Zabinski, PhD, Senior Director, AI & Personalized Medicine at OM1. The road to diagnosis can be taxing for patients and once diagnosed, personalized treatment plans are still created with an element of guess work. Automation and artificial intelligence (AI) are the[…]
2022 Year in Review: Real-World Data & AI
2022 has been a busy and productive year for OM1 in Real-World Data (RWD), Real-World Evidence (RWE), and Artificial Intelligence (AI). In this debut newsletter, we highlight industry trends and how OM1 is rising to meet those challenges and innovating to develop new opportunities. Please complete the form to download the newsletter. Download >> *Due[…]